Navigation Links
Sinovac to Present at 2009 UBS Global Life Sciences Conference
Date:9/16/2009

BEIJING, Sept. 16 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that Mr. Weidong Yin, Chairman, President & CEO, will present at the 2009 UBS Global Life Sciences Conference in New York City. The presentation is scheduled for Tuesday, September 22, 2009 at 9 a.m. Eastern time.

A live webcast of the presentation will be available online on the Investor Relations home page of the Sinovac's corporate Web site at http://www.sinovac.com .

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

    For more information, please contact:

     Helen G. Yang
     Sinovac Biotech Ltd.
     Tel:   +86-10-8289-0088 x9871
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

    Investors:
     Amy Glynn/Sara Pellegrino
     The Ruth Group
     Tel:   +1-646-536-7023/7002
     Email: aglynn@theruthgroup.com
            
'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Sinovac Closes $9.75 Million Private Placement
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
9. Sinovac Biotech Holds Annual General Meeting
10. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
11. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ( ... novel mid- to late-stage cardiovascular drug candidates, today ... its first round of financing. The Series A ... Hercules Bioventures with participation from investors that included ... executive, Dr. Larry Hsu , the founder ...
(Date:8/28/2014)... USA (PRWEB) August 27, 2014 Scientists, ... month for SPIE Laser Damage 2014 symposium. ... materials for high-power lasers will run 14-17 September. The ... for optics and photonics . , The premier conference ... understanding laser damage to optical materials will engage researchers ...
(Date:8/28/2014)... Earlier this month, a report ... with the U.S. Air Force on the performance of ... that this type of fuel made from mustard seeds, ... important to America’s Eco friendly future. In fact, every ... to become independent of foreign oil over the next ...
(Date:8/28/2014)... 28, 2014 Supplementing their complete ... promotion for Eppendorf Safe Lock Centrifuge Tubes ... the highest quality tubes at an affordable price. ... customers doing chemical, medical, pharmaceutical, and life science ... not regularly able to afford Eppendorf products. , ...
Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... N.J., July 21 BioNeutral Group, Inc. ("BioNeutral") (OTC ... Science Company announced today that at ATS Labs using ... Antimicrobial passed the difficult Quantitative Disk Carrier test ... difficile (C.diff) present in this test ...
... , , PALO ALTO, Calif., July 21, ... third quarter of its fiscal year 2009 after 1:00 p.m. Pacific Time ... of its investor conference call to review those quarterly results is scheduled ... , That live webcast can be accessed from Varian, ...
... , , KENILWORTH, N.J., July 21 ... for the 2009 second quarter. , , ... given us the strength to again power through tough challenges - delivering ... Fred Hassan, chairman and CEO. , , ...
Cached Biology Technology:BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 3Schering-Plough Reports Financial Results for 2009 Second Quarter 2Schering-Plough Reports Financial Results for 2009 Second Quarter 3Schering-Plough Reports Financial Results for 2009 Second Quarter 4Schering-Plough Reports Financial Results for 2009 Second Quarter 5Schering-Plough Reports Financial Results for 2009 Second Quarter 6Schering-Plough Reports Financial Results for 2009 Second Quarter 7Schering-Plough Reports Financial Results for 2009 Second Quarter 8Schering-Plough Reports Financial Results for 2009 Second Quarter 9Schering-Plough Reports Financial Results for 2009 Second Quarter 10Schering-Plough Reports Financial Results for 2009 Second Quarter 11Schering-Plough Reports Financial Results for 2009 Second Quarter 12Schering-Plough Reports Financial Results for 2009 Second Quarter 13Schering-Plough Reports Financial Results for 2009 Second Quarter 14Schering-Plough Reports Financial Results for 2009 Second Quarter 15Schering-Plough Reports Financial Results for 2009 Second Quarter 16Schering-Plough Reports Financial Results for 2009 Second Quarter 17Schering-Plough Reports Financial Results for 2009 Second Quarter 18Schering-Plough Reports Financial Results for 2009 Second Quarter 19Schering-Plough Reports Financial Results for 2009 Second Quarter 20Schering-Plough Reports Financial Results for 2009 Second Quarter 21Schering-Plough Reports Financial Results for 2009 Second Quarter 22Schering-Plough Reports Financial Results for 2009 Second Quarter 23Schering-Plough Reports Financial Results for 2009 Second Quarter 24Schering-Plough Reports Financial Results for 2009 Second Quarter 25Schering-Plough Reports Financial Results for 2009 Second Quarter 26Schering-Plough Reports Financial Results for 2009 Second Quarter 27
(Date:8/27/2014)... NY (June, 2014) Outstanding basic research, a ... a dedication to patient care have earned the ... University Medical Center (CUMC) and NewYork-Presbyterian Hospital an ... the National Cancer Institute (NCI). The grant renews ... NCI-designated Comprehensive Cancer Centers in New York City ...
(Date:8/27/2014)... number of studies have shown that excessive ... of Parkinson,s disease. Previous studies from Chunyan ... in China have shown that baicalin prevented ... divalent metal transporter 1 expression, and increased ... of rotenone-induced Parkinson,s disease rats. However, the ...
(Date:8/27/2014)... of seven hours ago the Happy Camp Complex of ... California, the July complex had consumed 35,530 as of ... fires on the Happy Camp Ranger District of the ... area on August 11, 2014. All but three of ... is a list of contained fires and their size ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Happy Camp and July Fire Complexes in California 2
... your body is telling you that your pace feels a little ... A new study, published online March 18 in the ... human running varies with speed and that each individual has an ... distance with the least effort. The result debunks the ...
... millions of people with diseases that starve eye tissue ... procedure being developed by researchers at Oak Ridge National ... of Tennessee. The technique uses a new class ... tissue being deprived of oxygen because of restricted blood ...
... of the benefits of cooling strategies to protect the ... to a wealth of cutting edge research, prime examples ... of Journal of Neurotrauma , a peer-reviewed journal ... The issue will be available free online at ...
Cached Biology News:Optimum running speed is stride toward understanding human body form 2ORNL, Southern Cal set sights on preventing blindness 2Therapeutic hypothermia is promising strategy to minimize tissue damage 2
... 25-Hydroxy Vitamin D kit is an ... of 25-hydroxyvitamin D (25-OH D) and ... or plasma. Our patented DIRECT assay ... precipitation and centrifugation and therefore facilitates ...
... The IDS Corticosterone kit is a competitive ... corticosterone in mouse or rat serum or ... sole, corticosteroid in rats and mice, and ... birds and reptiles. Most mammals produce both ...
Mouse monoclonal [BC-4] to Aggrecan xxPEN ( Abpromise for all tested applications). entrezGeneID: 176 SwissProtID: P16112...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Biology Products: